Search
Infants with cystic fibrosis (CF) develop structural lung disease early in life, and viral infections are associated with progressive lung disease. We hypothesized that the presence of respiratory viruses would be associated with structural lung disease on computed tomography (CT) of the chest in infants with CF.
Promising results from an Australian-led clinical trial could drastically change the way we care for young children with cystic fibrosis (CF).
De novo S. aureus acquisition at age 3 is associated with later bronchiectasis and FEF25-75 in children with CF
Whether airway mucosal acidification drives early progressive lung disease is controversial
This study demonstrates the feasibility of utilizing pre-clinical in vitro culture models to screen therapeutic candidates
Our data associates IL-1α with early structural lung damage in CF and suggests this pathway as a novel anti-inflammatory target
A The Kids Research Institute Australia spin-off company has received $20 million from the Medical Research Commercialisation Fund to develop a promising new therapy for the treatment of Cystic Fibrosis.
The family of two girls with cystic fibrosis are hopeful after The Kids Research Institute Australia spin-off company, Respirion, receives $20 million in funding to develop a promising new therapy.
Positive expiratory pressure devices are frequently used for airway clearance in children with cystic fibrosis and tracheobronchomalacia. This study aimed to establish if electrical impedance tomography is a feasible measure to titrate pressures in non-sedated children.
Two researchers from The Kids Research Institute Australia’s Wal-yan Respiratory Research Centre have secured lucrative fellowships to advance cutting-edge phage therapy research for people living with cystic fibrosis (CF).